{"keywords":["Brain metastases","Crizotinib","Non-small cell lung cancer","ROS1","Radiotherapy"],"meshTags":["Carcinoma, Non-Small-Cell Lung","Adult","Protein-Tyrosine Kinases","Female","Brain Neoplasms","Proto-Oncogene Proteins","Lung Neoplasms","Gene Rearrangement","Humans"],"meshMinor":["Carcinoma, Non-Small-Cell Lung","Adult","Protein-Tyrosine Kinases","Female","Brain Neoplasms","Proto-Oncogene Proteins","Lung Neoplasms","Gene Rearrangement","Humans"],"genes":["ROS1 rearranged non-small cell lung cancer brain metastases","ROS1 gene","ROS","proto-oncogene tyrosine protein kinase","ROS1","NSCLC brain metastases"],"organisms":["9606","9606"],"publicationTypes":["Case Reports","Journal Article"],"abstract":"We present a young woman with ROS1 gene rearranged non-small cell lung cancer (NSCLC) with brain metastases. ROS is a proto-oncogene tyrosine protein kinase. The patient received a partial course of whole brain radiation therapy and experienced a sustained partial response in the brain. We hypothesize that ROS1 rearranged NSCLC brain metastases may be particularly sensitive to radiation therapy. ","title":"ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy.","pubmedId":"26159887"}